INTRODUCTION: Vitamin D is a fat-soluble prohormone and was identified after the discovery of the anti-rachitic effect of cod liver oil somewhere in the early part of the 20th century. This vitamin which was found in cod liver oil was assigned as “vitamin D” following Vitamin A, B and C. Vitamin D has two major biologically inert precursors, vitamin D3 (Cholecalciferol) and vitamin D2 (Ergocalciferol). Out of these precursors, vitamin D3 is formed from 7-dehydrocholesterol present in the skin, which following exposure to solar ultraviolet B (UVB, 290-320 nm), is converted to previtamin D3. Previtamin D3 is immediately converted to vitamin D in a heat dependent process. Moreover excess of UVB rays also transform previtamin D3 into biologically inactive metabolites, tachysterol and lumisterol. On the other hand, the other precursor vitamin D2 is plant derived and its source is through diet. Vitamin D has both endocrine and autocrine functions. The endocrine role of vitamin D is mainly in serum calcium homeostasis.

The autocrine effects of vitamin D depend mainly on genetic transcription specific to the various types of cells expressing nuclear vitamin D receptors. These functions lead to inhibition of cell proliferation, promotion of cell differentiation and apoptosis. Thus vitamin D has an important role in modulation of calcium homeostasis, cardiovascular dynamics, musculoskeletal health and genetic expression. In Dermatology, topical vitamin D and its analogues are being used since time immemorial in various conditions like vitiligo, psoriasis in the form calcitriol, calcipotriol, etc. Recently vitamin D deficiency and its reduced levels in serum has been seen in various skin diseases.

BIOCHEMISTRY AND PHYSIOLOGY OF VITAMIN D: The primary form of vitamin D is cholecalciferol [25 (OH) D3], which is synthesized in the liver and is the form used to measure the levels of vitamin D in the blood whereas the active form of vitamin D [1, 25-(OH)2 D3] is a secosteroid (Steroid with an opened B-ring) hormone and is synthesized in the kidney via the hydroxylation of 25(OH)D3 by 1α-hydroxylase. This active form of vitamin D is the one that is important in various functions like regulation of calcium and bone metabolism, cellular proliferation and differentiation and
immunoregulation. It is because of this range of functions that vitamin D has been exploited clinically to treat various disorders like secondary hyperparathyroidism, osteoporosis, psoriasis, and vitiligo. Recent advances and novel insights in the understanding of 1, 25(OH)2 D3, its functions and mechanisms of its immunomodulatory properties suggest a wider utility and role of this hormone in the treatment of various autoimmune diseases and inflammatory disorders.

**VITAMIN D PATHWAY IN SKIN:** The skin is the only tissue in the human body yet known which incorporates complete Ultraviolet-B induced pathway from 7-dehydrocholesterol to the hormonally active calcitriol under normal physiological conditions. The synthesis of calcitriol in the epidermis is fundamentally important because it regulates important cellular functions in keratinocytes and immunocompetent cells. The UVB action spectrum that is responsible for the sunburn response and photocarcinogenesis is involved in vitamin D biosynthesis. The conversion of previtamin D3 to the inactive photoproducts lumisterol and tachysterol is an important step as it balances the cutaneous biosynthesis of vitamin D3 as a feedback mechanism. This mechanism keeps a check on “overdose” of vitamin D3 by photoexposure alone.

**VITAMIN D USES IN DERMATOLOGICAL CONDITIONS:**

- **PSORIASIS:** Psoriasis is a common Th1 mediated chronic inflammatory skin disease. Various studies have shown a prevalence of 2-3% for psoriasis in the world population. Recent studies carried out among psoriasis patients have shown deficiency of serum concentration of 25(OH) vitamin D3 in these patients and further evidence is growing. Psoriasis involves altered secretion of cAMP by the epidermal keratinocytes. Dysfunction of these and other peptides has been involved in the pathogenesis of psoriasis and many other inflammatory skin diseases. Also LL-37, the only cathelicidin present in humans has been found to be over expressed in the inflamed skin of patients of psoriasis. Vitamin D3 is directly involved in the regulation of the expression of cathelicidins. Topical forms of vitamin D have been used in psoriasis. These bind to vitamin D receptors (VDRs) over keratinocytes and leads to transcription of genes and influencing the growth and differentiation of keratinocytes in psoriatic skin.

- **VITILIGO:** Vitiligo is a common skin condition with well-defined depigmented patches and macules over skin and is characterized by destruction of melanocytes. According to the convergence theory various factors like autoimmunity, accumulation of melanocyte toxic chemicals, genetic predisposition and defective free radical clearance lead to the development of vitiliginous skin. The serum vitamin D levels are lower in vitiligo patients as compared to non vitiligo patients. In vitro studies have shown that murine B-16 melanoma cells when treated with vitamin D3 exhibit an increase in tyrosinase activity and melanogenesis. The presence of melanosomes at more advanced stages when seen through electron microscopy on treatment with 1, 25(OH)2 D3 further substantiates the role of vitamin D in vitiligo. Topical Vitamin D3 analogues like calcipotriol either alone or in combination with PUVA, NB-UVB are new therapeutic modalities and these act through the vitamin D receptors.

- **ATOPIC DERMATITIS:** Atopic dermatitis is a common skin condition characterized by impaired and dysfunctional skin barrier system and a dominant Th2 response. Genetic factors like filaggerin mutation and environmental factors both contribute to atopic dermatitis. 1, 25 (OH)2 vitamin D3 exerts its effects through VDRs present in human epidermis. VDRs are present in a
variable distribution in human epidermis with more concentration in the basal epidermis. VDRs are also located on the macrophages and dendritic cells. 1, 25, (OH)2 vitamin D3 acts on these VDRs and results in increased IL-10 production, regularizes cathelicidin production, suppresses the inflammatory response and helps in restoring the integrity of the impaired permeability barrier.20

- **ACNE VULGARIS:** It is a disorder of the pilosebaceous follicles involving mainly the face, chest, back and shoulders. It involves four main processes which include hyperkeratinization of the pilosebaceous follicles, increased sebum production, increased propionobacterium colonization and inflammation.21 Also it has been known that inflammatory cytokines play a major role in the pathophysiology of acne. These inflammatory cytokines are produced from the sebocytes as well as keratinocytes. Recently it has been shown in various studies that vitamin D does influence the expression of these cytokines thus proving beneficial in acne.22

- **HAIR DISORDERS:** Various animal studies have shown the role of Vitamin D in hair cycle and has also found beneficial effects of vitamin D analogues in various hair disorders. These studies suggest an important role of VDRs independent of vitamin D3 in hair follicle cycle, specifically “Anagen” initiation. But studies on humans using vitamin D analogues are limited. However few studies have found a protective role of calcitriol against chemotherapy induced alopecia caused by paclitaxel and cyclophosphamide.23

- **AUTOIMMUNE DISORDERS:** The role of vitamin D on the immune system has been studied a lot. VDRs are present in significant concentrations on immature thymus cells, macrophages and CD8 lymphocytes. Vitamin D has been known to stimulate the transforming growth factor beta-1 and interleukin-4 thus resulting in suppression of inflammatory T cells. All these actions have led to the role of vitamin D in autoimmune disorders.24 Various studies have shown that vitamin D supplementation has been found useful in various autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus. One study even found that supplementation with Vitamin D in SLE patients resulted in improvement in disease activity score and proteinuria.25

**VITAMIN D3 ANALOGUES:** Over the past few years, vitamin D analogues have found a significant place in Dermatology as a therapeutic entity. Various vitamin D analogues discovered are calcipotriol, maxacalcitol, tacalcitol and calcitriol. These agents have been shown to be minimally absorbed systemically and have been even involved with phototherapy and other systemic agents in conditions like vitiligo and psoriasis.

**CONCLUSION:** Vitamin D has always been known to be an important nutrient for human body. Recently its role in the pathophysiology of various biological functions has been studied and its role in various dermatological and non-dermatological diseases has gained much impetus. But more studies are required to establish its role in management of various disorders.

**REFERENCES:**

1. Vitwolpowitz D, Gilchrest BA. The vitamin D questions: how much do you need and how should you get it. J Am Acad Dermatol 2006; 54: 301-317.
2. Holick MF. The use and interpretation of assays for vitamin D and its metabolites. J Nutr 1990; 120 (Suppl):1464-1469.
3. Vieth R. Why "vitamin D" is not a hormone, and not a synonym for 1, 25 dihydroxy vitamin D, its analogs and deltanoids. J Steroid Biochem Mol Biol 2004; 89-90:571-573.
4. LoPiccolo MC, Lim HW. Vitamin D in health and disease. Photodermatol Photoimmunol Photomed. 2010; 26(5):224-229.
5. Reddy K.K., Gilchrest B.A. What is all this commotion about vitamin D? J Invest Dermatol. 2010; 130(2):321-326.
6. Tsiaras WG, Weinstock MA. Factors influencing vitamin D status. Acta Derma Venereol. 2011; 91(2):115–124.
7. Van Etten E, Mathieu C. Immunoregulation by 1, 25-dihydroxyvitaminD3: Basic concepts. J Steroid Biochem Mol Biol 2005; 97:93.
8. Mora JR, Iwata M, Von Adrian UH. Vitamin effects on the immune system. Vitamins A and D take center stage. Nat Rev Immunol 2008; 8: 685-98.
9. Heaney R.P. Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008; 3(5):1535–1541.
10. Lehmann B, Meurer M. Vitamin D metabolism. Dermatol Ther. 2010; 23(1):2–12.
11. Reddy KK, Gilchrest BA. What is all this commotion about vitamin D? J Invest Dermatol. 2010; 130 (2):321–326.
12. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15:16-7.
13. Dombrowski Y, Schaub J. Cathelicidin LL-37: A defense molecule with a potential role in psoriasis pathogenesis. Exp Dermatol 2012; 21: 327-30.
14. Rohm M, Agerberth B, Ahangari G, Ståhle-Bäckdahl M, Lidén S, Wigzell H, et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997; 272:15258-63.
15. Dombrowski Y, Peric M, Koglin S, Ruzicka T, Schaub J. Control of cutaneous antimicrobial peptides by vitamin D3. Arch Dermatol Res 2010; 302:401-8.
16. Tanghetti A. The role of topical vitamin D modulators in psoriasis therapy. Journal of Drugs in Dermatology 2008; 8(8):4-8.
17. Birlea S, Birlea M, Cimponeriu D, Apostol P. Autoimmune diseases and vitamin D receptor Apa-I polymorphism are associated with vitiligo in a small inbred Romanian community. Acta Dermato-Venereologica 2006; 86:209–214.
18. Watabe H, Soma Y, Kawa Y, Ito M, Ooka S, Ohsumi K, et al. Differentiation of murine melanocyte precursors induced by 1, 25-dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. J Invest Dermatol 2002; 119:583-9.
19. Kabashima K. New concepts of pathogenesis of atopic dermatitis: interplay among the barrier, allergy and pruritus as a trinity. J Dermatol Sci 2013; 70(1):3-11.
20. Hata TR, Kotol P, Jackson M, Gallo RL. Administration of oral vitamin D induces cathelicin production in atopic individuals. J Allergy Clin Immunol. 2008; 122(4):829-31.
21. Iraji F, Sadeghnia A, Shahmoradi Z, Siadat AH, Jooya A. Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian J Dermatol Venereol Leprol 2007; 73:94-6.
22. Lee WJ, Choi HY, Sohn MY, Lee SJ, Kim DW. Expression of inflammatory biomarkers from cultured sebocytes was influenced by treatment with vitamin D. Indian J of Dermatol 2013; 58(4):327.
23. Jimenez JJ, Yunis AA. Vitamin D3 and chemotherapy induced alopecia. Nutrition.1996; 12:448-9.
24. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J.2001; 15(14):2579-85.
25. Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematous: modest association with disease activity and urine protein to keratinize ratio. Arthritis Rheum 2013; 65(7):1865-71.

AUTHORS:
1. Rohini Sharma
2. Sameer Abrol
3. Amit Badgal
4. Shokat Chowdhary

PARTICULARS OF CONTRIBUTORS:
1. Senior Resident, Department of Dermatology, GMC Jammu, J & K, India.
2. Senior Resident, Department of Medicine, GMC Jammu, J & K, India.
3. Senior Resident, Department of Medicine, MMMCH, Solan, India.
4. Assistant Professor, Department of Medicine, GMC Jammu, J & K, India.

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Dr. Rohini Sharma,
Senior Resident,
Department of Dermatology,
GMC Jammu, J & K, India.
E-mail: dr.rohini_sharma@yahoo.co.in

Date of Submission: 14/01/2015.
Date of Peer Review: 16/10/2015.
Date of Acceptance: 23/01/2015.
Date of Publishing: 31/01/2015.